Page 17 - Linical Evolution News Today

According to the company’s 12th Annual Pharmaceutical Innovation Report, pharmaceutical R&D return on investment has climbed to its highest peak since 2014.

A leader from the company discusses challenges in control labs and shares how a new solution aims to clear some key obstacles to greater effectiveness.

With the amount of available data increasing and technology evolving, says a company leader, the job of data manager is more demanding than ever before.

The company plans to launch a Phase Ib/II study of its compound NVG-291 in collaboration with researchers at Northwestern University’s Shirley Ryan AbilityLab.

Joining with a noted research foundation, the group is aiming for earlier detection and treatment of the disease, which hits nearly 500K people annually.

The collaboration will center on development of unique data sets, which could be used in helping promote better understanding of aspects of human health.

A forward-looking report from company experts includes a breakdown of the top trends to watch for in pharmaceutical development and in healthcare overall.

An AI expert discusses progress in the field, gaps in understanding, and how predictive modeling and other advanced analytical tools could be put to use.

A leader from the clinical trial technology company says that insights gained during the recent pandemic could be helpful in realizing future improvements.

OSP’s list of the year’s most-read stories shows readers are interested in M&A activities, new drug candidates, COVID-19 developments, and other hot news.